<DOC>
	<DOC>NCT00879554</DOC>
	<brief_summary>The purpose of the study is to determine safety and tolerability of CVX-045 in patients with advanced solid tumors.</brief_summary>
	<brief_title>A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Confirmed advanced solid tumors unresponsive to currently available therapies, or for which there is no standard therapy. Adequate coagulation, liver and renal function. Candidate for DCEMRI evaluation. ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1. Evidence of bleeding problems. Uncontrolled hypertension. Certain gastrointestinal problems including fistula and abscess. Patients with primary brain cancer.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>CVX-045</keyword>
</DOC>